Müller Glial Kir4.1 Channel Dysfunction in APOE4 ‐ KI Model of Alzheimer's Disease
Glia · 2026
DOI: 10.1002/glia.70119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glia, 2026. Verfasst von Surabhi D Abhyankar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Potassium Channels, Inwardly Rectifying, Ependymoglial Cells, Alzheimer Disease, Apolipoprotein E4. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIDDK NIH HHS, National Eye Institute.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD), particularly late‐onset AD (LOAD), affects millions worldwide, with the apolipoprotein ε 4 ( APOE4 ) allele being a significant genetic risk factor. Retinal abnormalities are a hallmark of LOAD, and our recent study demonstrated significant age‐related retinal impairments in APOE4 ‐knock‐in (KI) mice, highlighting that retinal impairments occur before the onset of cognitive decline in these mice. Müller cells (MCs), key retinal glia, are vital for retinal health, and their dysfunction may contribute to retinal impairments seen in AD. MCs maintain potassium balance via specialized inwardly rectifying K + channels 4.1 (Kir4.1). This study posits that Kir4.1 channels will be impaired in APOE4 ‐KI, resulting in MC dysfunction. Additionally, we demonstrate that MC dysfunction in APOE4 ‐KI stems from alterations in mitochondrial dynamics and oxidative stress. Kir4.1 expression and function were studied using immunofluorescence and through the whole‐cell voltage clamp, respectively. In parallel, rat Müller cells (rMC‐1) were used to create an in vitro model for further mechanistic studies. MitoQ was used to evaluate its potential to mitigate APOE4 ‐induced deficits. APOE4 retinas and APOE4 ‐transfected rMC‐1 significantly reduced Kir4.1 expression, K+ buffering capacity, and increased mitochondrial damage. APOE4 ‐transfected rMC‐1 showed reduced mitochondrial membrane potential (ΔΨm) and increased mitochondrial reactive oxygen species (ROS). MitoQ treatment significantly reduced mitochondrial ROS and restored Kir4.1 expression in APOE4 ‐expressing cells. Our results demonstrate that APOE4 causes mitochondrial dysfunction and MC impairment, which may contribute to retinal pathology in AD. MitoQ restored mitochondrial health and Kir4.1 expression in APOE4 ‐expressing rMC‐1, suggesting targeting mitochondria may offer a promising therapeutic strategy for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Biology, School of Science, Indiana University, Indianapolis, Indiana, USA.
- Stark Neurosciences Research Institute, Indianapolis, Indiana, USA.
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Förderung
- NEI NIH HHS
- NIDDK NIH HHS
- National Eye Institute
- Research to Prevent Blindness
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Abhyankar, S. D., Xiao, Y., Mahajan, N., Luo, Q., Cummins, T. R., Oblak, A. L., Lamb, B. T., Corson, T. W., & Bhatwadekar, A. D. (2026). Müller Glial Kir4.1 Channel Dysfunction in APOE4 ‐ KI Model of Alzheimer's Disease. Glia. https://doi.org/10.1002/glia.70119
Vancouver
Abhyankar SD, Xiao Y, Mahajan N, Luo Q, Cummins TR, Oblak AL, et al. Müller Glial Kir4.1 Channel Dysfunction in APOE4 ‐ KI Model of Alzheimer's Disease. Glia. 2026. doi:10.1002/glia.70119
BibTeX
@article{Abhyankar2026,
author = {Abhyankar, Surabhi D and Xiao, Yucheng and Mahajan, Neha and Luo, Qianyi and Cummins, Theodore R and Oblak, Adrian L and Lamb, Bruce T and Corson, Timothy W and Bhatwadekar, Ashay D},
title = {Müller Glial Kir4.1 Channel Dysfunction in APOE4 ‐ KI Model of Alzheimer's Disease},
journal = {Glia},
year = {2026},
doi = {10.1002/glia.70119}
}
EUVIMED